The pharmacology of endosomal TLR agonists in viral disease

被引：29

作者：

Averett, D. R. ^{[1
]}

Fletcher, S. P. ^{[1
]}

Li, W. ^{[1
]}

Webber, S. E. ^{[1
]}

Appleman, J. R. ^{[1
]}

机构：

[1] Anadys Pharmaceut Inc, San Diego, CA 92121 USA

来源：

BIOCHEMICAL SOCIETY TRANSACTIONS | 2007年 / 35卷

关键词：

antiviral immunity; imiquimod; interferon alpha (IFN alpha); isatoribine; pattern-recognition receptor; Toll-like receptor agonism (TLR agonism);

D O I：

10.1042/BST0351468

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The discovery of endosomal TLRs (Toll-like receptors) and their natural ligands has accelerated efforts to exploit them for therapeutic benefit. importantly, this was preceded by clinical exploration of agents now known to be endosomal TLR agonists. Clinical effects in viral disease have been reported with agonists of TLR3, TLR7, TLR7/8 and TLR9, and the TLR7 agonist imiquimod is marketed for topical use against warts, a papillomavirus disease. The observed pre-clinical and clinical profiles of agonists of each of these TLRs suggest induction of a multifaceted innate immune response, with biomarker signatures indicative of type 1 interferon induction. However, these agents differ in both their pharmaceutical characteristics and the cellular distribution of their target TLRs, suggesting that drugs directed to these targets will display differences in their overall pharmacological profiles.

引用

页码：1468 / 1472

页数：5

共 55 条

[1] Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct ctokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells [J].